Rajaratnam Vilashini, Islam Mohammad Mohiminul, Yang Maixee, Slaby Rachel, Ramirez Hilda Martinez, Mirza Shama Parveen
Department of Chemistry & Biochemistry, University of Wisconsin-Milwaukee, 3210 N. Cramer Street, Milwaukee, WI 53201, USA.
Cancers (Basel). 2020 Apr 10;12(4):937. doi: 10.3390/cancers12040937.
Glioblastoma is one of the most common and detrimental forms of solid brain tumor, with over 10,000 new cases reported every year in the United States. Despite aggressive multimodal treatment approaches, the overall survival period is reported to be less than 15 months after diagnosis. A widely used approach for the treatment of glioblastoma is surgical removal of the tumor, followed by radiotherapy and chemotherapy. While there are several drugs available that are approved by the Food and Drug Administration (FDA), significant efforts have been made in recent years to develop new chemotherapeutic agents for the treatment of glioblastoma. This review describes the molecular targets and pathogenesis as well as the current progress in chemotherapeutic development and other novel therapies in the clinical setting for the treatment of glioblastoma.
胶质母细胞瘤是最常见且最具危害性的实体脑肿瘤之一，在美国每年有超过10000例新发病例。尽管采用了积极的多模式治疗方法，但据报道，诊断后的总生存期不足15个月。治疗胶质母细胞瘤的一种广泛使用的方法是手术切除肿瘤，随后进行放疗和化疗。虽然有几种药物已获美国食品药品监督管理局（FDA）批准，但近年来人们仍在大力研发用于治疗胶质母细胞瘤的新型化疗药物。本综述描述了胶质母细胞瘤的分子靶点和发病机制，以及临床环境中化疗药物研发和其他新型疗法的当前进展。
